Workflow
CIRC(01763)
icon
Search documents
中国同辐(01763) - 自愿性公告 - 中国同辐新型碳-13呼气分析仪获批上市
2025-09-08 13:19
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 新型Su π one 13C呼氣分析儀檢測結果穩定,檢測效率高,一組樣本的檢測時間從 行業最少2分鐘縮短至30秒,有效改善應用體驗;憑藉「更高的檢測精度」,可適 配更廣泛的幽門螺桿菌規模化篩查場景,提升醫療資源利用效率,為我國構建胃 癌早篩早診防控體系增添關鍵技術支撐。 (股份代號:1763) 自願性公告 中國同輻新型碳-13呼氣分析儀獲批上市 本公告乃中國同輻股份有限公司(「中國同輻」或「本公司」)自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣布,近日,由中國同輻獨立自主研製的新型Su π one 13C呼氣 分析儀順利取得第二類醫療器械註冊證,實現幽門螺桿菌呼氣檢測技術的自主突 破,為幽門螺桿菌診斷提供更可靠、更高效、更便捷的解決方案。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 (於中華人民共和國註冊成立的股份有限 ...
中国同辐(01763) - 截至二零二五年八月三十一日止月份之股份发行人的证券变动月报表
2025-09-01 08:42
FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 2. 股份分類 | ...
中国同辐中期股东应占溢利同比增加11.33%
Core Insights - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 1.69% [2] - Shareholders' profit attributable to the company was 172 million RMB, showing an increase of 11.33% year-on-year [2] - The basic earnings per share were 0.54 RMB [2] Business Focus - The company is concentrating on two main industries: nuclear medical health and irradiation applications [2] - It provides comprehensive solutions in nuclear medicine and radiotherapy, forming a "6+N" industrial layout centered around isotopes, nuclear pharmaceuticals, nuclear medical equipment, and irradiation applications [2] - The business scope includes research, manufacturing, and sales of isotopes, radioactive drugs, and radiation sources, as well as irradiation sterilization, material modification, and EPC services for irradiation devices [2]
中国同辐(01763.HK):上半年权益股东应占利润1.72亿元 同比增加11.3%
Ge Long Hui· 2025-08-28 15:35
Core Viewpoint - China Dongfang (01763.HK) reported a revenue of RMB 2.858 billion for the six months ending June 30, 2025, representing a year-on-year increase of 2% [1] Financial Performance - Gross profit amounted to RMB 1.460 billion, showing a slight decrease of 0.3% year-on-year [1] - Profit attributable to equity shareholders was RMB 172 million, reflecting an increase of 11.3% year-on-year [1] - Basic earnings per share were RMB 0.54 [1] Margin Analysis - The gross margin decreased from 52.1% to 51.1% [1] - The decline in gross profit and gross margin was primarily due to a reduction in revenue from nuclear medicine, while other business segments with higher revenue growth had lower gross margins, which negatively impacted the overall gross margin [1]
中国同辐发布中期业绩 股东应占溢利1.72亿元 同比增加11.33%
Zhi Tong Cai Jing· 2025-08-28 14:30
Core Viewpoint - China Dongfang (01763) reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The company's profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year, with basic earnings per share of 0.54 RMB [1] - A mid-term dividend of 0.0807 RMB per share is proposed [1] Group Focus - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core businesses: radionuclides, radiopharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] Business Operations - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1] - It provides services such as irradiation sterilization, material modification, and the design, manufacturing, installation engineering, procurement, and construction (EPC) services of irradiation devices [1] - Additionally, the company offers nuclear medical equipment and construction services for nuclear medicine departments to hospitals and other medical institutions [1]
中国同辐(01763)发布中期业绩 股东应占溢利1.72亿元 同比增加11.33%
智通财经网· 2025-08-28 14:27
Group 1 - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year [1] - The basic earnings per share were 0.54 RMB, and the company proposed an interim dividend of 0.0807 RMB per share [1] Group 2 - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core business areas: radionuclides, nuclear pharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1]
中国同辐(01763) - 截至2025年6月30日止六个月之中期股息
2025-08-28 14:11
EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國同輻股份有限公司 | | 股份代號 | 01763 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期(半年期) | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.0807 RMB | | 股東批准日期 | 2025年9月17日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD, 金額有待公佈 | | 匯率 | ...
中国同辐(01763) - 2025 - 中期财报
2025-08-28 14:06
[Company Profile](index=3&type=section&id=Company%20Profile) China Isotope & Radiation Corporation, established in 1983, is a leading enterprise in China's isotope and radiation application field with 42 years of experience, focusing on nuclear medicine and radiation applications, forming a "6+N" industrial layout, and serving over 18,000 medical institutions - China Isotope & Radiation Corporation is a leading enterprise in China's isotope and radiation application field, with **42 years of industry experience**, and is a high-tech enterprise with the most comprehensive product range and industrial chain globally in isotopes, their products, and radiation processing[5](index=5&type=chunk)[6](index=6&type=chunk)[8](index=8&type=chunk) - The company's business focuses on two major industrial directions: nuclear medical health and radiation application, forming a "6+N" industrial layout centered on 6 major businesses including nuclides, radiopharmaceuticals, nuclear medical equipment, integrated nuclear medicine solutions, radiation sources and applications, and radiation applications[6](index=6&type=chunk)[8](index=8&type=chunk) - As of June 30, 2025, the company has formed a network of **37 medical centers**, has **8 R&D and production bases**, serves over **18,000 medical institutions**, and serves over **60 million people annually**[9](index=9&type=chunk)[10](index=10&type=chunk) - In recent years, the company has accounted for nearly **70%** of the large Class A radiotherapy equipment approved by the National Health Commission, becoming the leading brand for Class A radiotherapy equipment[9](index=9&type=chunk)[10](index=10&type=chunk) [Company Information](index=5&type=section&id=Company%20Information) This section provides basic company information for China Isotope & Radiation Corporation, including legal name, registered office, and principal place of business, along with key contact details for the board of directors, committees, legal advisors, auditors, and H-share registrar - The company's legal name is China Isotope & Radiation Corporation[12](index=12&type=chunk) - Changes in the board of directors include Mr. Han Yongjiang's resignation as Chairman on July 4, 2025, and Mr. Xiao Yafei's appointment as the new Chairman on July 25, 2025[12](index=12&type=chunk)[13](index=13&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk)[18](index=18&type=chunk)[19](index=19&type=chunk) - The Supervisory Committee was dissolved as of June 3, 2025, with all supervisors stepping down[19](index=19&type=chunk)[24](index=24&type=chunk)[292](index=292&type=chunk) [Definitions](index=11&type=section&id=Definitions) This section defines key terms and abbreviations used in the report, covering professional vocabulary related to corporate governance, related parties, financial indicators, and laws and regulations, ensuring clarity and consistency [Highlights](index=15&type=section&id=Highlights) During the reporting period, China Isotope & Radiation Corporation achieved significant progress in various areas, including the full industrial chain integration of carbon-14 isotopes, partial production capability at the North China base, and the entry of Fluorine [18F] Betaprazine Injection into Phase III clinical trials - On May 16, 2025, the first batch of commercial reactor-produced **carbon-14 isotope products** from CNNC Qin Tong was launched, marking the full industrial chain integration of China's carbon-14 isotope from independent R&D and production to market supply[28](index=28&type=chunk)[30](index=30&type=chunk) - On July 3, 2025, some workshops at Atom High-Tech's North China base achieved full production capability, marking an important step in automated radiopharmaceutical production[28](index=28&type=chunk)[31](index=31&type=chunk) - On May 27, 2025, the Phase III clinical trial for **Fluorine [18F] Betaprazine Injection** was initiated, bringing new hope for Alzheimer's disease diagnosis[34](index=34&type=chunk)[36](index=36&type=chunk) - In March 2025, the company successfully signed a contract for the supply of equipment for a **million-Curie design source loading irradiation facility in Bangladesh**, achieving a new breakthrough in overseas irradiation facility projects[35](index=35&type=chunk)[39](index=39&type=chunk) - On March 17, 2025, China Isotope & Radiation Corporation's **CyberKnife** received **19 Class A large medical equipment configuration permits** for 2024, accounting for **68%**[35](index=35&type=chunk)[40](index=40&type=chunk) - In June 2025, China Isotope & Radiation Corporation's **Carbon [14C] Barium Carbonate products** achieved batch export to Europe and America for the first time, establishing sales cooperation with leading enterprises in multiple countries[48](index=48&type=chunk)[50](index=50&type=chunk) - In July 2025, China Isotope & Radiation Corporation was again recognized as a "**Benchmark**" enterprise in the State-owned Assets Supervision and Administration Commission's (SASAC) scientific reform initiative[53](index=53&type=chunk)[56](index=56&type=chunk) [Financial Highlights](index=20&type=section&id=Financial%20Highlights) For the six months ended June 30, 2025, China Isotope & Radiation Corporation achieved revenue of RMB 2,857,764 thousand, a year-on-year increase of 1.7%, with operating profit and profit attributable to equity holders of the company both increasing, and basic earnings per share reaching RMB 0.54 2025 H1 Key Financial Data | Indicator | For the six months ended June 30, 2025 (RMB thousands) | For the six months ended June 30, 2024 (RMB thousands) | Year-on-year change (%) | | :--- | :--- | :--- | :--- | | Revenue | 2,857,764 | 2,810,279 | 1.7% | | Gross Profit | 1,459,529 | 1,464,150 | -0.3% | | Operating Profit | 457,569 | 409,429 | 11.8% | | Profit Before Tax | 431,130 | 392,273 | 9.9% | | Profit Attributable to Equity Holders of the Company | 171,994 | 154,496 | 11.3% | | Basic/Diluted Earnings Per Share (RMB) | 0.54 | 0.48 | 12.5% | | Gross Margin | 51.1% | 52.1% | -1.0pp | | Operating Profit Margin | 16.0% | 14.6% | 1.4pp | | Net Profit Margin | 11.9% | 10.9% | 1.0pp | **Balance Sheet (Period End):** | Indicator | As of June 30, 2025 (RMB thousands) | As of December 31, 2024 (RMB thousands) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 15,651,793 | 14,767,361 | 6.0% | | Total Liabilities | 7,691,302 | 7,022,766 | 9.5% | | Net Assets | 7,960,491 | 7,744,595 | 2.8% | [Management Discussion and Analysis](index=21&type=section&id=Management%20Discussion%20and%20Analysis) This section details China Isotope & Radiation Corporation's operating performance, business segment development, market expansion, scientific innovation, digital transformation, capital operations, capacity building, ecosystem co-construction, quality and safety management, future development strategies, and key risks for the first half of 2025 - The Group's operating revenue for the first half of 2025 reached **RMB 2,857.8 million**, a year-on-year increase of **1.7%**; net profit was **RMB 341.0 million**, a year-on-year increase of **11.2%**; and net profit attributable to owners of the parent company was **RMB 172.0 million**, a year-on-year increase of **11.3%**[59](index=59&type=chunk)[61](index=61&type=chunk) - The company focuses on two major industrial directions: nuclear medical health and radiation application, forming a "6+N" industrial layout, primarily engaged in the R&D, manufacturing, and sale of nuclides, radiopharmaceuticals, and radiation source products, and providing irradiation sterilization, material modification, and EPC services[58](index=58&type=chunk)[60](index=60&type=chunk) [Business Review](index=21&type=section&id=Business%20Review) As of June 30, 2025, China Isotope & Radiation Corporation operates five business segments, with sustained market expansion efforts in the first half of the year, achieving continuous growth in economic benefits, with operating revenue increasing by 1.7% year-on-year, and net profit and net profit attributable to owners of the parent company both achieving double-digit growth 2025 H1 Key Financial Indicators | Indicator | Amount (RMB millions) | Year-on-year growth (%) | | :--- | :--- | :--- | | Operating Revenue | 2,857.8 | 1.7% | | Net Profit | 341.0 | 11.2% | | Net Profit Attributable to Owners of the Parent Company | 172.0 | 11.3% | [Business Segments](index=22&type=section&id=Business%20Segments) The Group operates five segments: radiopharmaceuticals, radiation source products, irradiation, nuclear medical equipment and related services, and other businesses; radiopharmaceutical revenue declined due to reduced demand and increased competition in the breath test market 2025 H1 Revenue by Business Segment | Business Segment | For the six months ended June 30, 2025 (RMB millions) | Percentage (%) | For the six months ended June 30, 2024 (RMB millions) | Percentage (%) | Year-on-year change (%) | | :--- | :--- | :--- | :--- | :--- | :--- | | Radiopharmaceuticals | 1,651.6 | 57.8 | 1,767.9 | 62.9 | -6.6% | | Radiation Source Products | 252.0 | 8.8 | 256.9 | 9.1 | -1.9% | | Irradiation | 88.7 | 3.1 | 86.5 | 3.1 | 2.5% | | Nuclear Medical Equipment and Related Services | 247.7 | 8.7 | 273.8 | 9.8 | -9.6% | | Other Businesses | 617.8 | 21.6 | 425.2 | 15.1 | 45.3% | | **Total** | **2,857.8** | **100.0** | **2,810.3** | **100.0** | **1.7%** | [Radiopharmaceuticals](index=22&type=section&id=Radiopharmaceuticals) Radiopharmaceutical business revenue decreased by 6.6% year-on-year, mainly due to reduced market demand and increased competition for breath test products, despite successful expansion in the fluorine drug market - Radiopharmaceutical business revenue was **RMB 1,651.6 million**, a year-on-year decrease of **6.6%**[66](index=66&type=chunk)[68](index=68&type=chunk) - Revenue from diagnostic and therapeutic radiopharmaceuticals was **RMB 847.9 million**, a year-on-year decrease of **1.9%**, with fluorine drug market expansion leading to a **12.8% increase** in revenue, but sodium iodide drug sales were affected by changes in clinical guidelines[66](index=66&type=chunk)[68](index=68&type=chunk) - Breath test revenue was **RMB 786.66 million**, a year-on-year decrease of **11.5%**, primarily due to reduced market demand and increased competition[66](index=66&type=chunk)[68](index=68&type=chunk) - The company launched the "Nuclide Therapy Work Strengthening and Efficiency Improvement Special Action Project" to enhance the level of grassroots nuclide targeted therapy and the influence of nuclear medicine[62](index=62&type=chunk)[64](index=64&type=chunk) [Radiation Source Products](index=24&type=section&id=Radiation%20Source%20Products) Revenue from radiation source products decreased by 1.9% year-on-year, mainly due to the prioritization of industrial radiation sources for internal group use, reducing external sales - Radiation source product revenue was **RMB 252.0 million**, a year-on-year decrease of **1.9%**[70](index=70&type=chunk)[73](index=73&type=chunk) - The decline in revenue was mainly due to the prioritization of industrial radiation sources for internal use by the Group, which reduced external sales[70](index=70&type=chunk)[73](index=73&type=chunk) - Market share for Gamma Knife sources and industrial radiography sources remained stable, and Phase I of the Jiajiang Radiation Source Base project is nearing production[69](index=69&type=chunk)[72](index=72&type=chunk) [Irradiation](index=25&type=section&id=Irradiation) Revenue from irradiation-related businesses increased by 2.5% year-on-year, primarily driven by an increase in irradiation sterilization volume - Irradiation-related business revenue was **RMB 88.7 million**, a year-on-year increase of **2.5%**[74](index=74&type=chunk)[77](index=77&type=chunk) - The increase in revenue was mainly due to a higher volume of irradiation sterilization services compared to the same period last year[74](index=74&type=chunk)[77](index=77&type=chunk) - Tianjin and Yulin irradiation projects are progressing as scheduled, aiming to build comprehensive sterilization service bases[75](index=75&type=chunk)[76](index=76&type=chunk) [Nuclear Medical Equipment and Related Services](index=26&type=section&id=Nuclear%20Medical%20Equipment%20and%20Related%20Services) Revenue from nuclear medical equipment and related services decreased by 9.6% year-on-year; despite the revenue decline, CNNC Accuray's CyberKnife system received 19 Class A large medical equipment configuration permits in 2024, accounting for 68%, demonstrating its leading position in the localization of high-end radiotherapy equipment - Nuclear medical equipment and related services revenue was **RMB 247.7 million**, a year-on-year decrease of **9.6%**[78](index=78&type=chunk)[80](index=80&type=chunk) - CNNC Accuray's X-ray stereotactic radiosurgery system (CyberKnife) received **19 Class A large medical equipment configuration permits** in 2024, accounting for **68%**[78](index=78&type=chunk)[79](index=79&type=chunk) [Other Businesses](index=27&type=section&id=Other%20Businesses) Revenue from trade services and other businesses increased by 45.3% year-on-year, with international business export revenue reaching a new high, growing by 63.4% - Trade services and other businesses revenue was **RMB 617.8 million**, a year-on-year increase of **45.3%**[82](index=82&type=chunk)[84](index=84&type=chunk) - International business export revenue was **RMB 349.5 million**, a year-on-year increase of **63.4%**, setting a new historical record[82](index=82&type=chunk)[84](index=84&type=chunk) - The company again won the bid for the Bangladesh irradiation facility project, helped domestic oil logging sources go global, and achieved the first batch export of domestic medical isotopes to Europe and America[82](index=82&type=chunk)[83](index=83&type=chunk) [Market Expansion](index=28&type=section&id=Market%20Expansion) China Isotope & Radiation Corporation continued to advance brand building and market promotion, participating in multiple important industry conferences and exhibitions to fully showcase its position in the nuclear technology application industry - The Group participated in the 2025 Radioactive Drug Innovation and Development Conference, the first China-Ocean Peace Use of Nuclear Technology Forum, etc., fully demonstrating its industry position[87](index=87&type=chunk)[88](index=88&type=chunk) - The company continued to promote sales model reform, fostering synergistic development of breath test products, radiopharmaceuticals, radiation sources, and radiotherapy equipment businesses[89](index=89&type=chunk)[91](index=91&type=chunk) - In collaboration with the Chinese Society of Nuclear Medicine, the company launched a demonstration project to promote nuclear medicine diagnosis and treatment work, completing the initiation of **5 demonstration projects** in grassroots hospitals during the reporting period[89](index=89&type=chunk)[91](index=91&type=chunk) [International Business](index=29&type=section&id=International%20Business) During the reporting period, China Isotope & Radiation Corporation actively expanded its international market, exporting products to dozens of countries and regions, achieving export revenue of RMB 349.5 million, a year-on-year increase of 63.4% - The Group exported products to dozens of countries and regions including Brazil, Peru, and Nigeria, achieving export revenue of **RMB 349.5 million**[90](index=90&type=chunk)[92](index=92&type=chunk) - Export revenue increased by **63.4%** year-on-year, with multiple breakthroughs in international business, including re-signing the Bangladesh irradiation facility project, repeat purchases of cold kits, and new registrations for breath diagnostic products in Saudi Arabia and Niger[90](index=90&type=chunk)[93](index=93&type=chunk) - The company actively promoted its role as an IAEA Collaborating Centre, assisted the Ministry of Commerce in organizing foreign aid training, and hosted the IAEA Conference on Radiation Science and Technology, enhancing its international influence[94](index=94&type=chunk)[97](index=97&type=chunk) [Scientific Research and Innovation](index=30&type=section&id=Scientific%20Research%20and%20Innovation) China Isotope & Radiation Corporation achieved significant results in scientific research and innovation, with a substantial increase in patent applications and grants, continuously strengthening its technological capabilities - As of June 30, 2025, the Group held **1,054 valid patents**, including **224 invention patents**, with **74 patent applications** and **106 patent grants** during the reporting period[96](index=96&type=chunk)[99](index=99&type=chunk) - Multiple diagnostic and therapeutic radiopharmaceuticals are in various clinical trial stages, including Fluorine [18F] Betaprazine Injection initiating Phase III clinical trials, and Iodine [131I]-MIBG Injection, Fluorine [18F] Fluciclovine Injection, etc., undergoing Phase III clinical trials[95](index=95&type=chunk)[98](index=98&type=chunk) - The Group's first batch of commercial reactor-produced carbon-14 isotope products was launched, achieving full industrial chain integration; the production technology for carrier-free Lutetium-177 nuclide was introduced from ITM Group, establishing the first domestic production line with an annual capacity of **ten thousand Curies**[109](index=109&type=chunk)[111](index=111&type=chunk) - The independently developed Gamma Beam Stereotactic Radiosurgery System (Gamma Knife) received its medical device registration certificate on July 5, 2024, offering advantages of more precise, intelligent, and efficient treatment[110](index=110&type=chunk)[112](index=112&type=chunk) [Patents and Awards](index=30&type=section&id=Patents%20and%20Awards) During the reporting period, the company achieved significant results in intellectual property work, applying for 74 patents, obtaining 106 authorizations, and accumulating a total of 1,054 valid patents - During the reporting period, the Group applied for **74 patents** and obtained **106 patent grants**[96](index=96&type=chunk)[99](index=99&type=chunk) - As of June 30, 2025, the Group owned **1,054 valid patents**, including **224 invention patents**[96](index=96&type=chunk)[99](index=99&type=chunk) - During the reporting period, **7 trademarks** were registered, **9 copyrights** were registered, **1 national standard** and **2 national pharmacopoeia standards** were issued, and **2 national standards** are under compilation[96](index=96&type=chunk)[99](index=99&type=chunk) [Diagnostic Drugs](index=31&type=section&id=Diagnostic%20Drugs) The company made progress in the R&D of diagnostic drugs for tumors and neurodegenerative diseases, with patient enrollment for Phase III clinical trials of Iodine [131I] Metaiodobenzylguanidine Injection and Technetium [99mTc] Sulfur Colloid completed, and other drugs in Phase III trials - Patient enrollment for Phase III clinical trials of **Iodine [131I] Metaiodobenzylguanidine Injection** for pheochromocytoma diagnosis has been completed[101](index=101&type=chunk) - Phase III clinical trials for **Fluorine [18F] Fluciclovine Injection** for prostate cancer diagnosis are underway, expected to fill a domestic gap[101](index=101&type=chunk) - Patient enrollment for Phase III clinical trials of **Technetium [99mTc] Sulfur Colloid** for breast cancer sentinel lymph node imaging has been completed[102](index=102&type=chunk) - Phase I clinical trials for Alzheimer's disease (AD) diagnostic drug **Fluorine [18F] Betaprazine Injection** have been completed, and Phase III clinical trials have been initiated[104](index=104&type=chunk) - Phase III clinical trials for Parkinson's disease diagnostic drug **6-[18F] Fluoro-L-Dopa Injection** are underway, which will fill a domestic PET Parkinson's drug gap[104](index=104&type=chunk) [Theranostic Drugs](index=34&type=section&id=Theranostic%20Drugs) The company made progress in theranostic drugs for neuroendocrine tumors, with Gallium [68Ga] DOTATATE Injection and Lutetium [177Lu] Oxo-octreotide Injection currently undergoing Phase III clinical trials, expected to significantly improve diagnosis and treatment efficiency upon market launch - **Gallium [68Ga] DOTATATE Injection** and **Lutetium [177Lu] Oxo-octreotide Injection** are undergoing Phase III clinical trials, expected to significantly improve the diagnosis and treatment efficiency for neuroendocrine tumor patients[105](index=105&type=chunk)[107](index=107&type=chunk) [Oncology Therapeutic Drugs](index=34&type=section&id=Oncology%20Therapeutic%20Drugs) Palladium [103Pd] sealed seed source, an implantable product for brachytherapy, has completed all preclinical research, suitable for permanent implantation therapy for various solid tumors - **Palladium [103Pd] sealed seed source** has completed all preclinical research, suitable for brachytherapy of prostate cancer, pancreatic cancer, lung cancer, and other solid tumors[106](index=106&type=chunk)[108](index=108&type=chunk) [Nuclides](index=35&type=section&id=Nuclides) The Group successfully launched the first batch of commercial reactor-produced carbon-14 isotope products, achieving full industrial chain integration, and introduced carrier-free Lutetium-177 nuclide production technology, establishing the first domestic production line with an annual capacity of ten thousand Curies - The first batch of commercial reactor-produced **carbon-14 isotope products** was launched, achieving full industrial chain integration of China's carbon-14 isotope[109](index=109&type=chunk)[111](index=111&type=chunk) - The production technology for carrier-free **Lutetium-177 nuclide** was introduced from ITM Group, establishing the first domestic production line with an annual capacity of **ten thousand Curies**, with product indicators meeting European Pharmacopoeia requirements and GMP-grade production and supply capabilities[109](index=109&type=chunk)[111](index=111&type=chunk) [Nuclear Medical Equipment](index=35&type=section&id=Nuclear%20Medical%20Equipment) The Group's independently developed Gamma Beam Stereotactic Radiosurgery System (Gamma Knife) received its medical device registration certificate on July 5, 2024, offering advanced features for precise, intelligent, and efficient cancer treatment - The independently developed **Gamma Beam Stereotactic Radiosurgery System (Gamma Knife)** successfully received its medical device registration certificate on July 5, 2024[110](index=110&type=chunk)[112](index=112&type=chunk) - The Gamma Knife features kV cone-beam CT image guidance, sub-millimeter automatic correction with a six-dimensional couch, high dose rate, and AI-driven automatic organ contouring, enabling more precise, intelligent, and shorter single-treatment times[110](index=110&type=chunk)[112](index=112&type=chunk) [R&D Platforms](index=36&type=section&id=R%26D%20Platforms) China Isotope & Radiation Corporation possesses a comprehensive internal and external R&D platform system, including multiple external platforms and internal R&D centers, actively collaborating with top research institutions and universities, and strengthening high-level talent development with 670 R&D personnel - The Group owns external R&D platforms such as the IAEA Collaborating Centre for Radiopharmaceuticals and Radiation Sources, and the National Atomic Energy Agency Nuclear Technology (Radiopharmaceutical Engineering Transformation) R&D Center[113](index=113&type=chunk)[114](index=114&type=chunk) - Internal R&D centers include the Radiopharmaceutical R&D Center, Stable Isotope and Breath Test Technology R&D Center, Radiation Source and Application R&D Center, and Radiation Application Technology R&D Center[115](index=115&type=chunk)[117](index=117&type=chunk) - The company actively establishes scientific research cooperation with leading domestic research institutes, universities, and hospitals such as the National Institute of Metrology, Shanghai Institute of Materia Medica, Beijing Normal University, and Peking Union Medical College Hospital, and has **670 R&D personnel**[115](index=115&type=chunk)[117](index=117&type=chunk)[118](index=118&type=chunk) [Digital Transformation](index=38&type=section&id=Digital%20Transformation) China Isotope & Radiation Corporation actively promotes digital transformation, researching overall solutions and ensuring project organization and resource allocation, while exploring AI+nuclear technology applications and accelerating industrial digitalization - The Group actively promotes digital transformation, researching overall solutions and ensuring project organization and resource allocation[119](index=119&type=chunk)[120](index=120&type=chunk) - Promoting the "Nuclear Smart Hub" ERP system, completing business standard dissemination and difference identification analysis, and entering the solution adaptation phase[119](index=119&type=chunk)[120](index=120&type=chunk) - Actively exploring new scenarios for AI+nuclear technology applications, conducting research and project initiation for AI applications in scientific innovation fields such as radiopharmaceutical R&D[119](index=119&type=chunk)[120](index=120&type=chunk) - Accelerating industrial digitalization, conducting self-assessment of smart manufacturing maturity, advancing the construction of isotope-related smart factories, and building a digital platform for production quality[119](index=119&type=chunk)[120](index=120&type=chunk) [Capital Operations](index=39&type=section&id=Capital%20Operations) During the reporting period, China Isotope & Radiation Corporation did not add new external equity investment projects, while its innovation industry investment fund, with a paid-in capital balance of RMB 410 million, introduced new investors and primarily invests in nuclear technology applications - During the reporting period, the Group had no new external equity investment projects[121](index=121&type=chunk)[123](index=123&type=chunk) - As of June 30, 2025, the company's paid-in capital balance in the CIRC Innovation Industry Investment Fund was **RMB 410 million**, accounting for **45.08%**[121](index=121&type=chunk)[124](index=124&type=chunk) - The CIRC Fund introduced the National Military-Civilian Integration Industry Investment Fund and the Beijing Daxing Development Guidance Fund, enhancing its capital advantages, primarily investing in nuclear technology application fields, with some invested enterprises planning independent listings[122](index=122&type=chunk)[125](index=125&type=chunk) [Production Capacity and Base Construction](index=40&type=section&id=Production%20Capacity%20and%20Base%20Construction) To meet the demand for radiopharmaceuticals, China Isotope & Radiation Corporation accelerated the national layout of medical centers and base construction, enhancing production capacity, with key projects like the North China, East China, and South China medical bases, and the Jiajiang Radiation Source Base, progressing steadily - The national network layout of medical centers continues to expand, with **29 operating centers** accumulated, including the completion and production of Technetium drug production lines in Guiyang and Urumqi[126](index=126&type=chunk)[128](index=128&type=chunk) - Phase I hot testing of some production lines at the North China Medical Base has been completed, equipment installation at the East China Medical Base project has been completed, and the South China Base has initially completed the adjustment plan for its project proposal[126](index=126&type=chunk)[128](index=128&type=chunk) - Phase II of the High-Enrichment 13CO Gas Enrichment Construction Project has completed preliminary feasibility studies; once completed, it will become the first **ton-level** high-enrichment 13CO gas production base in China[129](index=129&type=chunk)[130](index=130&type=chunk) - Phase I of the Jiajiang Radiation Source R&D and Production Base project passed the review by the National Nuclear Safety Expert Committee, and the Qinshan Isotope Production Base project completed hot testing for carbon-14 and strontium-89[129](index=129&type=chunk)[130](index=130&type=chunk) - The Tianjin Irradiation Project officially commenced construction, and the Zhangjiagang Gamma Irradiation Facility Renovation Project significantly improved production efficiency, capacity, and product quality[129](index=129&type=chunk)[130](index=130&type=chunk) [Co-building a Nuclear Medicine Development Ecosystem](index=42&type=section&id=Co-building%20a%20Nuclear%20Medicine%20Development%20Ecosystem) China Isotope & Radiation Corporation assisted 13 hospitals in the Western Sichuan region in forming a nuclide therapy alliance, creating a nuclide therapy network covering 20 million people, promoting regional coordinated development, and deepening strategic cooperation with the Chinese Society of Nuclear Medicine - The Group assisted **13 hospitals** in the Western Sichuan region in forming a nuclide therapy alliance, creating a nuclide therapy network covering **20 million people**, promoting regional disciplinary development from "single-point breakthroughs" to "regional coordination"[131](index=131&type=chunk)[133](index=133&type=chunk) - Deepening strategic cooperation with the Chinese Society of Nuclear Medicine, jointly promoting the construction of national nuclear medicine diagnosis and treatment demonstration bases; as of June 2025, **7 demonstration projects** have been initiated[132](index=132&type=chunk)[134](index=134&type=chunk) - Actively promoting the application of the "Fuzhi 1.0" smart nuclear medicine system and initiating the R&D of "Fuzhi 2.0," aiming to achieve inter-hospital connectivity and multi-center integrated diagnosis and treatment[135](index=135&type=chunk)[136](index=136&type=chunk) [Quality and Safety](index=44&type=section&id=Quality%20and%20Safety) In the first half of 2025, China Isotope & Radiation Corporation focused on "Year of Excellence" to comprehensively advance quality work, achieve quality objectives, and continuously carry out special actions to enhance the effectiveness of quality systems at medical centers, while maintaining a strong safety record - Quality objectives were met in the first half of the year, with the quality system fully established ahead of schedule and maintained in dynamic balance; special actions to enhance the effectiveness of quality systems at medical centers continued[137](index=137&type=chunk)[138](index=138&type=chunk) - No production safety or environmental accidents occurred from January to June; the three-year special action for fundamental safety production improvement was thoroughly implemented[139](index=139&type=chunk)[140](index=140&type=chunk) - A "full-scope, full-process, full-lifecycle" radiation safety management system was established, achieving steady improvement in safety management levels[139](index=139&type=chunk)[140](index=140&type=chunk) - In the first half of the year, **8 member units** successfully passed on-site assessments for safety production standardization, effectively enhancing enterprise safety production management[139](index=139&type=chunk)[140](index=140&type=chunk) [Future Development](index=46&type=section&id=Future%20Development) In the second half of 2025, China Isotope & Radiation Corporation will focus on high-quality stable growth, scientific innovation, market expansion, capacity building, and governance efficiency improvement, aiming to accelerate key product growth, international market expansion, and R&D progress - In the second half of the year, the focus will be on high-quality stable growth, expanding effective investment, accelerating the reservation of high-quality projects, and intensifying market breakthroughs to achieve stable growth in key products such as isotopes and their products, and nuclear medical equipment[141](index=141&type=chunk)[142](index=142&type=chunk) - Vigorously promoting scientific innovation, establishing a market-oriented scientific innovation system, advancing key R&D projects to achieve milestone progress, and accelerating clinical trials for **8 radiopharmaceuticals**[141](index=141&type=chunk)[143](index=143&type=chunk) - Strengthening market expansion, optimizing the distributor model, focusing on South America, Southeast Asia, the Middle East, North Africa, and countries along the "Belt and Road" to promote large-scale export of core products[144](index=144&type=chunk)[145](index=145&type=chunk) - Enhancing production capacity, accelerating the construction of three major key special projects, ensuring the Phase I production of the Jiajiang Radiation Source Base and obtaining production licenses for Phase I of the North China Medical Base to start trial production[146](index=146&type=chunk) - Improving governance efficiency, compiling the "15th Five-Year Plan" with high standards, promoting the implementation of the excellent performance model and the online application of the "Nuclear Smart Hub" ERP, and safeguarding the bottom lines of safety, environmental protection, quality, and confidentiality[147](index=147&type=chunk) [Key Risks and Uncertainties](index=48&type=section&id=Key%20Risks%20and%20Uncertainties) China Isotope & Radiation Corporation faces various risks and uncertainties, including operational, investment, market, interest rate, liquidity, and economic environment risks, which could adversely affect its operating results and financial position - Operational risk: Risk of loss due to inadequate or missing internal procedures, personnel, or systems, or due to external events[148](index=148&type=chunk)[150](index=150&type=chunk)[152](index=152&type=chunk) - Investment risk: The possibility of any investment incurring a loss relative to its expected return; the company has established an authorization system and conducts detailed analysis[148](index=148&type=chunk)[151](index=151&type=chunk)[153](index=153&type=chunk) - Market risk: Risk of profitability being harmed or the ability to achieve business objectives being affected due to market competition[148](index=148&type=chunk)[154](index=154&type=chunk)[158](index=158&type=chunk) - Economic environment risk: The Group's majority of business is located in mainland China, and its operating results and financial position are affected by economic development in mainland China and other regions; an economic slowdown may have an adverse impact[148](index=148&type=chunk)[157](index=157&type=chunk)[161](index=161&type=chunk)[162](index=162&type=chunk) [Financial Review](index=50&type=section&id=Financial%20Review) The Group's revenue for the first half of 2025 increased by 1.7% year-on-year to RMB 2,857.8 million, primarily driven by increased revenue from other business segments, while gross profit slightly decreased, and operating profit and profit for the period both increased 2025 H1 Income Statement Key Data | Indicator | For the six months ended June 30, 2025 (RMB millions) | For the six months ended June 30, 2024 (RMB millions) | Year-on-year change (%) | | :--- | :--- | :--- | :--- | | Revenue | 2,857.8 | 2,810.3 | 1.7% | | Cost of Sales | 1,398.2 | 1,346.1 | 3.9% | | Gross Profit | 1,459.5 | 1,464.2 | -0.3% | | Gross Margin | 51.1% | 52.1% | -1.0pp | | Other Income, Gains and Losses | 46.9 | 26.0 | 80.5% | | Selling and Distribution Expenses | 601.9 | 678.2 | -11.2% | | Administrative Expenses, R&D Costs and Credit Impairment Losses | 447.0 | 402.6 | 11.0% | | Finance Costs | 29.8 | 24.1 | 23.8% | | Profit Before Tax | 431.1 | 392.3 | 9.9% | | Profit for the Period | 341.0 | 306.7 | 11.2% | [Revenue](index=50&type=section&id=Revenue) The Group's revenue primarily comes from five segments: radiopharmaceuticals, radiation source products, irradiation, nuclear medical equipment and related services, and other businesses, with total revenue increasing by 1.7% year-on-year to RMB 2,857.8 million - Revenue increased by **1.7%** year-on-year to **RMB 2,857.8 million**[163](index=163&type=chunk)[166](index=166&type=chunk) - Mainly due to increased revenue from the other business segment[163](index=163&type=chunk)[166](index=166&type=chunk) [Cost of Sales, Gross Profit and Gross Margin](index=50&type=section&id=Cost%20of%20Sales%2C%20Gross%20Profit%20and%20Gross%20Margin) Cost of sales increased by 3.9% year-on-year to RMB 1,398.2 million, mainly due to increased cost of sales in the other business segment, while gross profit decreased by 0.3% to RMB 1,459.5 million, and gross margin fell from 52.1% to 51.1% - Cost of sales increased by **3.9%** year-on-year to **RMB 1,398.2 million**[164](index=164&type=chunk)[167](index=167&type=chunk) - Gross profit decreased by **0.3%** year-on-year to **RMB 1,459.5 million**, with gross margin falling from **52.1% to 51.1%**[164](index=164&type=chunk)[168](index=168&type=chunk) - The decrease in gross profit and gross margin was mainly due to lower radiopharmaceutical revenue and the lower gross margin of the other business segment, which had a larger revenue increase[164](index=164&type=chunk)[168](index=168&type=chunk) [Other Income, Gains and Losses](index=50&type=section&id=Other%20Income%2C%20Gains%20and%20Losses) Other income, gains, and losses significantly increased by 80.5% year-on-year to RMB 46.9 million, primarily benefiting from increased government grants and dividend income - Other income increased by **80.5%** year-on-year to **RMB 46.9 million**[165](index=165&type=chunk)[169](index=169&type=chunk) - Mainly due to increased government grants and dividend income[165](index=165&type=chunk)[169](index=169&type=chunk) [Selling and Distribution Expenses](index=51&type=section&id=Selling%20and%20Distribution%20Expenses) Selling and distribution expenses decreased by 11.2% year-on-year to RMB 601.9 million, with the percentage of revenue falling from 24.1% to 21.1%, primarily due to reduced sales service fees resulting from changes in radiopharmaceutical sales policies - Selling and distribution expenses decreased by **11.2%** year-on-year to **RMB 601.9 million**[170](index=170&type=chunk)[174](index=174&type=chunk) - As a percentage of revenue, it decreased from **24.1% to 21.1%**[170](index=170&type=chunk)[175](index=175&type=chunk) - Mainly due to reduced sales service fees caused by changes in radiopharmaceutical sales policies[170](index=170&type=chunk)[174](index=174&type=chunk) [Administrative Expenses, Research and Development Costs and Credit Impairment Losses](index=51&type=section&id=Administrative%20Expenses%2C%20Research%20and%20Development%20Costs%20and%20Credit%20Impairment%20Losses) Administrative expenses, R&D costs, and credit impairment losses combined increased by 11.0% year-on-year to RMB 447.0 million, with the percentage of revenue rising from 14.3% to 15.6%, mainly due to increased staff costs and expensed R&D expenditures - Administrative expenses, R&D costs, and credit impairment losses combined increased by **11.0%** year-on-year to **RMB 447.0 million**[171](index=171&type=chunk)[176](index=176&type=chunk) - As a percentage of revenue, it increased from **14.3% to 15.6%**[171](index=171&type=chunk)[177](index=177&type=chunk) - Mainly due to increased staff costs and expensed R&D expenditures[171](index=171&type=chunk)[176](index=176&type=chunk) [Finance Costs](index=51&type=section&id=Finance%20Costs) Finance costs increased by 23.8% year-on-year to RMB 29.8 million, primarily due to increased interest expenses driven by the company's increased funding needs for business development - Finance costs increased by **23.8%** year-on-year to **RMB 29.8 million**[172](index=172&type=chunk)[178](index=178&type=chunk) - Mainly due to increased funding needs for the company's business development, leading to higher interest expenses[172](index=172&type=chunk)[178](index=178&type=chunk) [Share of Loss of Associates and Share of Profit of Joint Ventures](index=51&type=section&id=Share%20of%20Loss%20of%20Associates%20and%20Share%20of%20Profit%20of%20Joint%20Ventures) Share of loss of associates increased by 54.4% year-on-year to RMB 7.5 million, mainly due to a decrease in associate profits, while share of profit of joint ventures decreased by 7.7% year-on-year to RMB 10.9 million due to a slight decrease in joint venture profits - Share of loss of associates increased by **54.4%** year-on-year to **RMB 7.5 million**, mainly due to a decrease in associate profits[173](index=173&type=chunk)[179](index=179&type=chunk) - Share of profit of joint ventures decreased by **7.7%** year-on-year to **RMB 10.9 million**, mainly due to a slight decrease in joint venture profits[180](index=180&type=chunk)[185](index=185&type=chunk) [Profit Before Tax](index=52&type=section&id=Profit%20Before%20Tax) Considering the above factors, profit before tax increased by 9.9% year-on-year to RMB 431.1 million - Profit before tax increased by **9.9%** year-on-year to **RMB 431.1 million**[181](index=181&type=chunk)[186](index=186&type=chunk) [Income Tax Expense](index=52&type=section&id=Income%20Tax%20Expense) Income tax expense increased by 5.3% year-on-year to RMB 90.1 million, with the effective tax rate decreasing from 21.8% to 20.9% - Income tax expense increased by **5.3%** year-on-year to **RMB 90.1 million**[182](index=182&type=chunk)[187](index=187&type=chunk) - The effective tax rate decreased from **21.8% to 20.9%**[182](index=182&type=chunk)[187](index=187&type=chunk) [Profit for the Period](index=52&type=section&id=Profit%20for%20the%20Period) Considering the above factors, profit for the period increased by 11.2% year-on-year to RMB 341.0 million - Profit for the period increased by **11.2%** year-on-year to **RMB 341.0 million**[183](index=183&type=chunk)[188](index=188&type=chunk) [Financial Position](index=52&type=section&id=Financial%20Position) As of June 30, 2025, the Group's total assets, total liabilities, and net assets all increased, with net current assets growing by 7.7% and the adjusted net gearing ratio rising to 38.4% 2025 H1 Balance Sheet Overview | Indicator | As of June 30, 2025 (RMB millions) | As of December 31, 2024 (RMB millions) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 15,651.8 | 14,767.4 | 6.0% | | Total Liabilities | 7,691.3 | 7,022.8 | 9.5% | | Net Assets | 7,960.5 | 7,744.6 | 2.8% | [Overview](index=52&type=section&id=Overview) As of June 30, 2025, the Group's total assets increased to RMB 15,651.8 million, total liabilities to RMB 7,691.3 million, and net assets to RMB 7,960.5 million - As of June 30, 2025, the Group's total assets were **RMB 15,651.8 million**, total liabilities were **RMB 7,691.3 million**, and total equity was **RMB 7,960.5 million**[184](index=184&type=chunk)[189](index=189&type=chunk) [Net Current Assets](index=53&type=section&id=Net%20Current%20Assets) Net current assets increased by 7.7% from RMB 3,895.0 million as of December 31, 2024, to RMB 4,193.1 million as of June 30, 2025, primarily due to increases in prepayments and inventories Current Assets, Current Liabilities, and Net Current Assets | Indicator | As of June 30, 2025 (RMB millions) | As of December 31, 2024 (RMB millions) | | :--- | :--- | :--- | | Total Current Assets | 9,638.5 | 8,918.4 | | Total Current Liabilities | 5,445.4 | 5,023.4 | | Net Current Assets | 4,193.1 | 3,895.0 | - Net current assets increased by **7.7%** to **RMB 4,193.1 million**, mainly due to increases in prepayments and inventories[192](index=192&type=chunk)[193](index=193&type=chunk) [Adjusted Net Gearing Ratio and Quick Ratio](index=54&type=section&id=Adjusted%20Net%20Gearing%20Ratio%20and%20Quick%20Ratio) As of June 30, 2025, the adjusted net gearing ratio was 38.4% (34.9% as of December 31, 2024), and the quick ratio was 1.5 times (1.6 times as of December 31, 2024) Gearing Ratio and Quick Ratio | Indicator | As of June 30, 2025 | As of December 31, 2024 | | :--- | :--- | :--- | | Adjusted Net Gearing Ratio | 38.4% | 34.9% | | Quick Ratio | 1.5 times | 1.6 times | [Trade and Other Receivables](index=54&type=section&id=Trade%20and%20Other%20Receivables) As of June 30, 2025, net trade and other receivables amounted to RMB 5,135.7 million, after deducting an allowance for doubtful debts of RMB 276.6 million - As of June 30, 2025, trade and other receivables were **RMB 5,135.7 million**, after deducting an allowance for doubtful debts of **RMB 276.6 million**[195](index=195&type=chunk)[200](index=200&type=chunk) [Trade and Other Payables](index=54&type=section&id=Trade%20and%20Other%20Payables) As of June 30, 2025, trade and other payables amounted to RMB 4,086.9 million, primarily comprising trade payables, accrued expenses, and other payables - As of June 30, 2025, trade and other payables were **RMB 4,086.9 million**[196](index=196&type=chunk)[201](index=201&type=chunk) [Issuance of Bonds](index=54&type=section&id=Issuance%20of%20Bonds) On October 25, 2024, the company issued RMB 500 million of technology innovation corporate bonds with a coupon rate of 2.25%, maturing in 2027 - On October 25, 2024, the company issued **RMB 500 million** of corporate bonds with a coupon rate of **2.25%**, maturing in 2027[197](index=197&type=chunk)[202](index=202&type=chunk) [Bank Loans and Pledged Assets](index=55&type=section&id=Bank%20Loans%20and%20Pledged%20Assets) As of June 30, 2025, the Group's total bank loans amounted to RMB 2,086.34 million, including RMB 359.70 million borrowed from CNNC Finance, with assets pledged for borrowings totaling RMB 116.00 million - As of June 30, 2025, the Group's total bank loans were **RMB 2,086.34 million** (December 31, 2024: RMB 1,682.43 million)[203](index=203&type=chunk)[207](index=207&type=chunk) - Total loans from CNNC Finance were **RMB 359.70 million** (December 31, 2024: RMB 297.01 million)[203](index=203&type=chunk)[207](index=207&type=chunk) - As of June 30, 2025, assets pledged for borrowings amounted to **RMB 116.00 million**[203](index=203&type=chunk)[207](index=207&type=chunk) [Capital Expenditures](index=55&type=section&id=Capital%20Expenditures) During the reporting period, the Group's capital expenditures amounted to RMB 264.9 million, primarily for additions to property, plant, and equipment and intangible assets - During the reporting period, capital expenditures were **RMB 264.9 million**[204](index=204&type=chunk)[208](index=208&type=chunk) [Contingent Liabilities](index=55&type=section&id=Contingent%20Liabilities) As of June 30, 2025, the company had no significant contingent liabilities - As of June 30, 2025, the company had no significant contingent liabilities[205](index=205&type=chunk)[209](index=209&type=chunk) [Foreign Exchange and Exchange Rate Risk](index=55&type=section&id=Foreign%20Exchange%20and%20Exchange%20Rate%20Risk) The Group's revenue is primarily received in RMB, and some bank deposits denominated in foreign currencies (HKD) face currency risk, with the company monitoring foreign exchange movements but currently having no hedging policy - The Group's revenue is primarily received in RMB, and some bank deposits denominated in foreign currencies (HKD) face currency risk[206](index=206&type=chunk)[210](index=210&type=chunk) - The company monitors foreign exchange movements but currently has no foreign exchange hedging policy[206](index=206&type=chunk)[210](index=210&type=chunk) [Credit Risk](index=56&type=section&id=Credit%20Risk) The Group manages credit risk by continuously monitoring credit risk, investigating the creditworthiness of new customers, assessing credit quality, and defining credit limits, and believes there is no significant concentration of credit risk due to a large number of customers - The company has established policies to continuously monitor credit risk, conduct creditworthiness investigations for new customers, assess credit quality, and define credit limits[211](index=211&type=chunk)[212](index=212&type=chunk) - Given that trade receivables and bills receivable involve a large number of customers, the company believes there is no significant concentration of credit risk[213](index=213&type=chunk)[215](index=215&type=chunk) [Liquidity Risk](index=56&type=section&id=Liquidity%20Risk) The Group regularly monitors liquidity needs, maintaining sufficient cash reserves and committed funds to meet short-term and long-term liquidity requirements, and the directors believe the company has sufficient monetary capital to fund operations, thus posing no significant liquidity risk - The company regularly monitors liquidity needs, ensuring sufficient cash reserves and committed funds are maintained[214](index=214&type=chunk)[216](index=216&type=chunk) - The directors believe the company has sufficient monetary capital to fund operations, and therefore there is no significant liquidity risk[214](index=214&type=chunk)[216](index=216&type=chunk) [Dividend Policy](index=57&type=section&id=Dividend%20Policy) The company's dividend policy stipulates that 10% of the after-tax profit for the year must be allocated to the statutory surplus reserve, and discretionary surplus reserves may also be allocated, with dividend declaration decisions depending on operating results, cash flow, financial position, future prospects, and legal and contractual restrictions - When distributing after-tax profit for the year, the company shall allocate **10%** to the statutory surplus reserve; no further allocation is required when the accumulated amount exceeds **50%** of the registered capital[217](index=217&type=chunk)[218](index=218&type=chunk) - Dividends for domestic shares are declared and paid in RMB, while dividends for H-shares are declared in RMB and paid in HKD, with the exchange rate being the arithmetic average of the middle rates of HKD to RMB published by the People's Bank of China for the five business days preceding the declaration date[219](index=219&type=chunk)[221](index=221&type=chunk) - Dividend declaration decisions depend on operating results, cash flow, financial position, future prospects, and legal and contractual restrictions[220](index=220&type=chunk)[222](index=222&type=chunk) [Interim Dividend](index=59&type=section&id=Interim%20Dividend) The Board of Directors recommended an interim dividend of RMB 0.0807 per share (tax inclusive) for the six months ended June 30, 2025, totaling RMB 25,813,904.43, with payment expected by November 14, 2025, and applicable tax withholdings for non-resident enterprise shareholders and individual H-share holders - The Board of Directors recommended an interim dividend of **RMB 0.0807 per share** (tax inclusive) for the six months ended June 30, 2025, totaling **RMB 25,813,904.43**[223](index=223&type=chunk)[225](index=225&type=chunk) - The 2025 interim dividend is expected to be paid by **November 14, 2025**, with H-share dividends denominated in RMB and paid in HKD[223](index=223&type=chunk)[225](index=225&type=chunk) - The company will withhold and pay **10%** enterprise income tax for non-resident enterprise shareholders and individual income tax for individual H-share holders according to tax agreements between their countries of residence and China[224](index=224&type=chunk)[226](index=226&type=chunk)[227](index=227&type=chunk)[229](index=229&type=chunk) [Suspension of Share Register Closure](index=61&type=section&id=Suspension%20of%20Share%20Register%20Closure) To convene the extraordinary general meeting and distribute the 2025 interim dividend, the company will suspend share transfer registration from September 12 to September 17, 2025, and from September 23 to September 26, 2025, respectively, to determine shareholders eligible to attend the meeting and receive dividends - To convene the extraordinary general meeting, share transfer registration will be suspended from **September 12 to September 17, 2025**[231](index=231&type=chunk)[232](index=232&type=chunk)[234](index=234&type=chunk) - To receive the 2025 interim dividend, share transfer registration will be suspended from **September 23 to September 26, 2025**[231](index=231&type=chunk)[232](index=232&type=chunk)[234](index=234&type=chunk) [No Material Adverse Change](index=62&type=section&id=No%20Material%20Adverse%20Change) The directors confirmed that as of June 30, 2025, there have been no material adverse changes in the company's financial and operating conditions or prospects - As of June 30, 2025, there have been no material adverse changes in the company's financial and operating conditions or prospects[235](index=235&type=chunk)[237](index=237&type=chunk) [Events After Reporting Period](index=62&type=section&id=Events%20After%20Reporting%20Period) After the reporting period, in August 2025, China Baoyuan gratuitously transferred all its 108,085,353 domestic shares of the company to CNNC Group, with the transfer registration completed on August 21, 2025, making CNNC Group the direct controlling company - In August 2025, China Baoyuan gratuitously transferred all its **108,085,353 domestic shares** of the company to CNNC Group[236](index=236&type=chunk)[238](index=238&type=chunk) - The relevant share transfer registration was completed on **August 21, 2025**, making CNNC Group the direct controlling company of the company[236](index=236&type=chunk)[238](index=238&type=chunk) [Use of Proceeds from Initial Public Offering](index=62&type=section&id=Use%20of%20Proceeds%20from%20Initial%20Public%20Offering) The company's H-shares were listed on July 6, 2018, with net proceeds from the global offering of approximately HKD 1.69 billion, of which RMB 268.1 million was used for working capital and general corporate purposes, and RMB 536.1 million for selective mergers and acquisitions - Net proceeds from the global offering were approximately **HKD 1.69 billion**[239](index=239&type=chunk)[240](index=240&type=chunk) Use of Proceeds from IPO (as of June 30, 2025) | Purpose | Initial Allocation (RMB millions) | Amount Used as of June 30, 2025 (RMB millions) | Remaining Amount as of June 30, 2025 (RMB millions) | Expected Time to Fully Utilize Remaining Amount | | :--- | :--- | :--- | :--- | :--- | | Investment in production and R&D bases for diagnostic and therapeutic radiopharmaceuticals | 597.3 | 460.0 | 0.0 | - | | Establishment of new production facilities | 84.5 | 50.0 | 0.0 | - | | Investment in R&D of various diagnostic and therapeutic radiopharmaceuticals, raw materials for radiation source products, medical radioisotopes, and urea breath test products and related raw materials | 253.6 | 105.5 | 12.8 | 2025 | | Investment/Selective (Mergers and) Acquisitions | 286.5 | 536.1 | 0.0 | - | | Working capital and general corporate purposes | 143.3 | 268.1 | 0.0 | - | | **Total** | **1,432.5** | **1,419.7** | **12.8** | | - The actual timing of use for R&D investment projects may differ from expectations due to ongoing planning for some newly initiated projects, subject to actual project progress[243](index=243&type=chunk) [Employees and Remuneration Policy](index=64&type=section&id=Employees%20and%20Remuneration%20Policy) As of June 30, 2025, the Group employed 3,361 employees, with staff costs of approximately RMB 378.7 million, and its remuneration policy aims to incentivize and retain excellent employees by providing salaries, bonuses, and various benefits, including retirement, medical, and housing provident fund plans - As of June 30, 2025, the Group employed **3,361 employees** (June 30, 2024: 3,132 employees)[244](index=244&type=chunk)[246](index=246&type=chunk) - For the six months ended June 30, 2025, staff costs were approximately **RMB 378.7 million** (same period in 2024: RMB 378.5 million)[244](index=244&type=chunk)[246](index=246&type=chunk) - The company's remuneration policy aims to incentivize and retain excellent employees, providing salaries, bonuses, and employee benefits, including retirement benefit plans, medical and work injury insurance plans, and housing provident fund plans[244](index=244&type=chunk)[246](index=246&type=chunk)[247](index=247&type=chunk) [Hedging Activities](index=65&type=section&id=Hedging%20Activities) For the six months ended June 30, 2025, the Group did not enter into any hedging transactions for foreign exchange or interest rate risks - For the six months ended June 30, 2025, the Group did not enter into any hedging transactions for foreign exchange or interest rate risks[249](index=249&type=chunk)[253](index=253&type=chunk) [Significant Investments, Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures](index=65&type=section&id=Significant%20Investments%2C%20Acquisitions%20and%20Disposals%20of%20Subsidiaries%2C%20Associates%20and%20Joint%20Ventures) For the six months ended June 30, 2025, the Group had no significant investments, disposals, or acquisitions of subsidiaries, associates, and joint ventures - For the six months ended June 30, 2025, the Group had no significant investments, disposals, or acquisitions of subsidiaries, associates, and joint ventures[250](index=250&type=chunk)[254](index=254&type=chunk) [Future Plans for Material Investments or Capital Assets](index=65&type=section&id=Future%20Plans%20for%20Material%20Investments%20or%20Capital%20Assets) The Group will actively explore domestic and international investment opportunities to increase revenue sources, but as of the latest practicable date, the company has no specific future plans for material investments or acquisitions of capital assets - The Group will actively explore domestic and international investment opportunities, but as of the latest practicable date, the company has no specific future plans for material investments or acquisitions of capital assets[251](index=251&type=chunk)[252](index=252&type=chunk)[255](index=255&type=chunk) [Corporate Governance Report and Other Information](index=66&type=section&id=Corporate%20Governance%20Report%20and%20Other%20Information) This section outlines China Isotope & Radiation Corporation's corporate governance practices, including compliance with Appendix C1 of the Listing Rules and the Model Code for Securities Transactions, with ongoing efforts to enhance corporate governance, changes in board and supervisory committee members, and disclosure of interests - The company has adopted and complied with the principles and code provisions of Appendix C1 "Corporate Governance Code" of the Listing Rules[257](index=257&type=chunk)[259](index=259&type=chunk) - All directors confirmed strict compliance with the "Model Code for Securities Transactions by Directors of Listed Issuers" during the reporting period[258](index=258&type=chunk)[260](index=260&type=chunk)[261](index=261&type=chunk) - As of the date of this interim report, the company has appointed **four independent non-executive directors**, and the Audit and Risk Management Committee comprises two independent non-executive directors and one non-executive director[262](index=262&type=chunk)[264](index=264&type=chunk)[263](index=263&type=chunk)[265](index=265&type=chunk) - As of June 30, 2025, the company's total share capital was **RMB 319,874,900**, divided into **79,968,800 H-shares** and **239,906,100 domestic shares**, with no changes during the reporting period[268](index=268&type=chunk)[270](index=270&type=chunk) - As of June 30, 2025, directors and chief executives held no disclosable interests or short positions in shares[269](index=269&type=chunk)[271](index=271&type=chunk) - As of June 30, 2025, the company had no significant litigation or arbitration matters[283](index=283&type=chunk)[286](index=286&type=chunk) - During the reporting period, the company consistently complied with OFAC-related commitments[284](index=284&type=chunk)[287](index=287&type=chunk) [Compliance with Model Code for Securities Transactions](index=66&type=section&id=Compliance%20with%20Model%20Code%20for%20Securities%20Transactions) The Group has adopted a "Customized Code" no less stringent than Appendix C3 of the Listing Rules, and all directors confirmed strict compliance during the reporting period, with no violations by employees identified - The Group has adopted a "Customized Code" no less stringent than Appendix C3 "Model Code for Securities Transactions by Directors of Listed Issuers" of the Listing Rules[258](index=258&type=chunk)[260](index=260&type=chunk) - All directors confirmed strict compliance with the "Customized Code" during the reporting period, and the company found no violations by employees[258](index=258&type=chunk)[261](index=261&type=chunk) [Independent Non-Executive Directors](index=67&type=section&id=Independent%20Non-Executive%20Directors) The company has appointed a sufficient number of independent non-executive directors with appropriate professional qualifications or financial management expertise, as required by the Listing Rules, with four such directors appointed as of the interim report date - The company has appointed a sufficient number of independent non-executive directors with appropriate professional qualifications or financial management expertise as required by the Listing Rules[262](index=262&type=chunk)[264](index=264&type=chunk) - As of the date of this interim report, the company has appointed **four independent non-executive directors**, including Mr. Pan Zhaoguo, Ms. Chen Jingshan, Mr. Lu Chuang, and Mr. An Rui[262](index=262&type=chunk)[264](index=264&type=chunk) [Audit and Risk Management Committee](index=67&type=section&id=Audit%20and%20Risk%20Management%20Committee) As of the interim report date, the Audit and Risk Management Committee comprises two independent non-executive directors and one non-executive director, with terms of reference compliant with the Listing Rules, and has reviewed the Group's accounting principles, internal controls, and interim financial results - The Audit and Risk Management Committee comprises Mr. Pan Zhaoguo (Chairman), Mr. Lu Chuang, and Mr. Chen Zan, in compliance with the Listing Rules[263](index=263&type=chunk)[265](index=265&type=chunk) - The Committee has reviewed the accounting principles and practices adopted by the Group and discussed internal controls and financial reporting matters with management[263](index=263&type=chunk)[266](index=266&type=chunk) - On August 28, 2025, the Committee reviewed and confirmed the interim results announcement and unaudited condensed consolidated interim financial information for the six months ended June 30, 2025[263](index=263&type=chunk)[267](index=267&type=chunk) [Share Capital](index=68&type=section&id=Share%20Capital) As of June 30, 2025, the company's total share capital was RMB 319,874,900, divided into 79,968,800 H-shares and 239,906,100 domestic shares, with no changes during the reporting period - As of June 30, 2025, the company's total share capital was **RMB 319,874,900**[268](index=268&type=chunk)[270](index=270&type=chunk) - The share capital is divided into **79,968,800 H-shares** and **239,906,100 domestic shares**, with a par value of **RMB 1.00 per share**[268](index=268&type=chunk)[270](index=270&type=chunk) - The company's share capital remained unchanged during the reporting period[268](index=268&type=chunk)[270](index=270&type=chunk) [Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures](index=68&type=section&id=Directors%27%20and%20Chief%20Executive%27s%20Interests%20and%20Short%20Positions%20in%20Shares%2C%20Underlying%20Shares%20and%20Debentures) As of June 30, 2025, the company's directors and chief executive did not hold any interests or short positions in shares, underlying shares, and debentures required to be disclosed to the company and the Stock Exchange under Divisions 7 and 8 of Part XV of the Securities and Futures Ordinance - As of June 30, 2025, the company's directors and chief executive held no interests or short positions in shares, underlying shares, and debentures required to be disclosed to the company and the Stock Exchange[269](index=269&type=chunk)[271](index=271&type=chunk) [Substantial Shareholders' Interests and Short Positions in Shares and Underlying Shares](index=68&type=section&id=Substantial%20Shareholders%27%20Interests%20and%20Short%20Positions%20in%20Shares%20and%20Underlying%20Shares) As of June 30, 2025, CNNC Group and its subsidiaries (CIAE, NPIC, CNNC Fund, China Baoyuan) collectively held approximately 98.43% of the company's domestic share capital, with other major shareholders holding varying proportions of H-share interests Substantial Shareholders' Interests and Short Positions (as of June 30, 20
中国同辐(01763) - 临时股东会之代表委任表格
2025-08-28 13:59
臨時股東會之代表委任表格 | 本代表委任表格有關的H股╱內資 | | | --- | --- | | 本代表委任表格有關的股份數目 (附註1) 股份類別 | (附註1) | 本人╱吾等 (附註2) : CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1763) 為本人╱吾等之代表,代表本人╱吾等出席將於2025年9月17日(星期三)上午十時正假座中國北京市海淀區廠窪中 街66號4樓403室舉行之本公司2025年第二次臨時股東會(「臨時股東會」)及其續會並於會上按以下指示就臨時股東會 通告所載之決議案為本人╱吾等及代表本人╱吾等表決,及在沒有有關指示之情況下,則由本人╱吾等之受委任 代表自行酌情表決。除另有指明者外,本代表委任表格所用詞彙與本公司日期為2025年8月28日的通函(「該通函」) 所界定者具有相同涵義。 | | 普通決議案 | (附註4) 贊成 | 反對 | (附註4) | 棄權 | (附註4) | | --- | --- | --- | --- | --- | --- | --- | | 1. ...
中国同辐(01763) - 临时股东会通告
2025-08-28 13:50
香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負 責,對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本通告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1763) 臨時股東會通告 中國同輻股份有限公司(「本公司」)董事(「董事」)會(「董事會」)茲通告,本公司 謹定於2025年9月17日(星期三)上午十時正假座中國北京市海淀區廠窪中街66號4樓 403室以現場會議方式舉行2025年第二次臨時股東會(「臨時股東會」)以審議及酌情批 准本公司以下決議案(除另有指明者外,本通告所用詞彙與本公司日期為2025年8月28 日的通函(「該通函」)所界定者具有相同涵義): 普通決議案 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 – 2 – 1. 本公司將於2025年9月12日(星期五)至2025年9月17日(星期三)(包括首尾兩日)期間暫停辦理股 份過戶登記手續。於2025年9月17日(星期三)名列本公司股東名 ...